Home › Gilead Initiates Phase 3 Clinical Program For Tenofovir Alafenamide, A Novel Low-Dose Prodrug For The Treatment Of HIV
 

Keywords :   


Gilead Initiates Phase 3 Clinical Program For Tenofovir Alafenamide, A Novel Low-Dose Prodrug For The Treatment Of HIV

2013-01-24 09:30:00| drugdiscoveryonline News Articles

Gilead Sciences, Inc. recently announced the initiation of the first of two Phase 3 clinical trials (Study 104) evaluating a single tablet regimen containing tenofovir alafenamide (TAF) for the treatment of HIV-1 infection in treatment-naïve adults

Tags: the of program treatment

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
06.10Weekly Recap: Ontex Enters Agreement to Sell Brazilian Business, Winner Acquires Stake in GRI ...
06.10Tropical Storm Milton Graphics
06.10Tropical Storm Milton Public Advisory Number 4A
06.10Summary for Tropical Storm Milton (AT4/AL142024)
06.10Atlantic Tropical Weather Outlook
06.10Eastern North Pacific Tropical Weather Outlook
06.10Ex-cabinet secretary says 200,000 job is underpaid
06.10Hurricane Leslie Graphics
More »